168 related articles for article (PubMed ID: 29175782)
1. Improved in vitro and in vivo performance of carbamazepine enabled by using a succinic acid cocrystal in a stable suspension formulation.
Ullah M; Shah MR; Bin Asad MHH; Hasan SMF; Hussain I
Pak J Pharm Sci; 2017 Nov; 30(6):2139-2145. PubMed ID: 29175782
[TBL] [Abstract][Full Text] [Related]
2. The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance.
Ullah M; Hussain I; Sun CC
Drug Dev Ind Pharm; 2016; 42(6):969-76. PubMed ID: 26460090
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Influence of Various Polymers on Dissolution and Phase Behavior of Carbamazepine-Succinic Acid Cocrystal in Matrix Tablets.
Ullah M; Ullah H; Murtaza G; Mahmood Q; Hussain I
Biomed Res Int; 2015; 2015():870656. PubMed ID: 26380301
[TBL] [Abstract][Full Text] [Related]
4. Expedited Tablet Formulation Development of a Highly Soluble Carbamazepine Cocrystal Enabled by Precipitation Inhibition in Diffusion Layer.
Yamashita H; Sun CC
Pharm Res; 2019 Apr; 36(6):90. PubMed ID: 31016440
[TBL] [Abstract][Full Text] [Related]
5. Understanding impact of pre-dissolved polymers on dissolution behavior of soluble carbamazepine cocrystal.
Ullah M; Khan SA; Shah SM; Rabbani I; Sadozai SK; Abbas N; Bin Asad MHH; Badshah M; Hasan SMF; Hussain I
Pak J Pharm Sci; 2019 May; 32(3):1049-1055. PubMed ID: 31278719
[TBL] [Abstract][Full Text] [Related]
6. Effects of coformers on phase transformation and release profiles of carbamazepine cocrystals in hydroxypropyl methylcellulose based matrix tablets.
Qiu S; Li M
Int J Pharm; 2015 Feb; 479(1):118-28. PubMed ID: 25542989
[TBL] [Abstract][Full Text] [Related]
7. Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media.
Omori M; Watanabe T; Uekusa T; Oki J; Inoue D; Sugano K
Mol Pharm; 2020 Oct; 17(10):3825-3836. PubMed ID: 32870691
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Effects of a Polymer on the Surface Dissolution of Pharmaceutical Cocrystals Using Combined Experimental and Molecular Dynamics Simulation Approaches.
Kirubakaran P; Wang K; Rosbottom I; Cross RBM; Li M
Mol Pharm; 2020 Feb; 17(2):517-529. PubMed ID: 31887053
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of novel immediate release carbamazepine tablets: complexation with hydroxypropyl-β-cyclodextrin in the presence of HPMC.
Kou W; Cai C; Xu S; Wang H; Liu J; Yang D; Zhang T
Int J Pharm; 2011 May; 409(1-2):75-80. PubMed ID: 21371541
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the effect of hydroxypropyl methylcellulose on the phase transformation and release profiles of carbamazepine-nicotinamide cocrystal.
Li M; Qiu S; Lu Y; Wang K; Lai X; Rehan M
Pharm Res; 2014 Sep; 31(9):2312-25. PubMed ID: 24590881
[TBL] [Abstract][Full Text] [Related]
11. RELATIVE BIOAVAILABILITY STUDY OF SUCCINIC ACID COCRYSTAL TABLET AND MARKETED CONVENTIONAL IMMEDIATE RELEASE TABLET FORMULATION OF CARBAMAZEPINE 200 MG IN RABBITS.
Ullah M; Murtaza G; Hussain I
Acta Pol Pharm; 2016 Jul; 73(4):1023-1027. PubMed ID: 29648728
[TBL] [Abstract][Full Text] [Related]
12. Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.
Yamashita H; Sun CC
Pharm Res; 2017 Dec; 35(1):4. PubMed ID: 29288433
[TBL] [Abstract][Full Text] [Related]
13. Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion.
Boksa K; Otte A; Pinal R
J Pharm Sci; 2014 Sep; 103(9):2904-2910. PubMed ID: 24807421
[TBL] [Abstract][Full Text] [Related]
14. Stable carbamazepine colloidal systems using the cosolvent technique.
Douroumis D; Fahr A
Eur J Pharm Sci; 2007 Apr; 30(5):367-74. PubMed ID: 17234395
[TBL] [Abstract][Full Text] [Related]
15. A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME.
Huang S; O'Donnell KP; Keen JM; Rickard MA; McGinity JW; Williams RO
AAPS PharmSciTech; 2016 Feb; 17(1):106-19. PubMed ID: 26335416
[TBL] [Abstract][Full Text] [Related]
16. Material-Sparing and Expedited Development of a Tablet Formulation of Carbamazepine Glutaric Acid Cocrystal- a QbD Approach.
Yamashita H; Sun CC
Pharm Res; 2020 Jul; 37(8):153. PubMed ID: 32705421
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
Liu C; Liu Z; Chen Y; Chen Z; Chen H; Pui Y; Qian F
Eur J Pharm Biopharm; 2018 Mar; 124():73-81. PubMed ID: 29305142
[TBL] [Abstract][Full Text] [Related]
18. Carbamazepine/betaCD/HPMC solid dispersions. I. Influence of the spray-drying process and betaCD/HPMC on the drug dissolution profile.
Koester LS; Mayorga P; Bassani VL
Drug Dev Ind Pharm; 2003 Feb; 29(2):139-44. PubMed ID: 12648010
[TBL] [Abstract][Full Text] [Related]
19. Thermally reversible in situ gelling carbamazepine liquid suppository.
El-Kamel A; El-Khatib M
Drug Deliv; 2006; 13(2):143-8. PubMed ID: 16423803
[TBL] [Abstract][Full Text] [Related]
20. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine).
Javadzadeh Y; Jafari-Navimipour B; Nokhodchi A
Int J Pharm; 2007 Aug; 341(1-2):26-34. PubMed ID: 17498898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
